Therapeutic role of a vaccine targeting RANKL and TNF-α on collagen-induced arthritis

Biomaterials

Volumn 33, Issue 32, 2012, Pages 8177-8185

  Yuan, Huihui ^a   Qian, Hongyan ^a   Liu, Sibo ^a   Zhang, Xulong ^a   Li, Shentao ^a   Wang, Wei ^a   Li, Zhanguo ^b   Jia, Junhui ^c   Zhao, Wenming ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b PEKING UNIVERSITY   (China)

^c CHINA AEROSPACE SCIENCE AND INDUSTRY CORPORATION   (China)

Author keywords

Collagen induced arthritis (CIA); Polypeptide vaccine; Receptor activator of NF B (RANKL); Tumor necrosis factor (TNF )

Indexed keywords

BONE DISEASE; BONE RESORPTION; COLLAGEN-INDUCED ARTHRITIS; FUSION PROTEINS; IN-VITRO; MICE MODELS; MOLECULAR-BIOLOGICAL TECHNIQUES; OSTEOCLASTOGENESIS; RECEPTOR ACTIVATOR; RHEUMATOID ARTHRITIS; SINGLE-AGENT; THERAPEUTIC EFFECTS; TUMOR NECROSIS FACTORS;

ANTIBODIES; BONE; CELL DEATH; GLYCOPROTEINS; MACROPHAGES; MAMMALS;

VACCINES;

ANTIBODY; ANTISERUM; HYBRID PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; RANKL TNF LIKE CORE FUSION PROTEIN VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTHRITIS; ARTICLE; CACHEXIA; CELL STRAIN L 929; CONTROLLED STUDY; CYTOTOXICITY TEST; DISEASE SEVERITY; DRUG CYTOTOXICITY; FEMALE; HYPERCALCEMIA; IMMUNIZATION; INCIDENCE; MORTALITY; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY FORMATION; ARTHRITIS, EXPERIMENTAL; BONE AND BONES; CELL LINE; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; RANK LIGAND; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR-ALPHA; VACCINES;

MUS;

EID: 84865539128     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.07.047     Document Type: Article

References (47)

1. Carmona L., Cross M., Williams B., Lassere M., March L. Rheumatoid arthritis. Best Pract Res Clin Rheumatol 2010, 24:733-745.
2. Smolen J.S., Aletaha D., Redlich K. The pathogenesis of rheumatoid arthritis: new insights from old clinical data?. Nat Rev Rheumatol 2012, 8:235-243.
3. Lubberts E., van den Berg W.B. Cytokines in the pathogenesis of rheumatoid arthritis and collagen-induced arthritis. Adv Exp Med Biol 2003, 520:194-202.
4. Herman S., Kronke G., Schett G. Molecular mechanisms of inflammatory bone damage: emerging targets for therapy. Trends Mol Med 2008, 14:245-253.
5. Abe T., Takeuchi T. Rheumatoid arthritis and tumor necrosis factor alpha. Autoimmunity 2001, 34:291-303.
6. Asagiri M., Takayanagi H. The molecular understanding of osteoclast differentiation. Bone 2007, 40:251-264.
7. van Tuyl L.H., Voskuyl A.E., Boers M., Geusens P., Landewe R.B., Dijkmans B.A., et al. Baseline RANKL: OPG ratio and markers of bone and cartilage degradation predict annual radiological progression over 11 years in rheumatoid arthritis. Ann Rheum Dis 2010, 69:1623-1628.
8. Anandarajah A.P. Role of RANKL in bone diseases. Trends Endocrinol Metab 2009, 20:88-94.
9. Mewar D., Wilson A.G. Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors. Br J Pharmacol 2011, 162:785-791.
10. Wong B.R., Rho J., Arron J., Robinson E., Orlinick J., Chao M., et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997, 272:25190-25194.
11. Shibata H., Yoshioka Y., Ohkawa A., Minowa K., Mukai Y., Abe Y., et al. Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist. J Biol Chem 2008, 283:998-1007.
12. Ta H.M., Nguyen G.T., Jin H.M., Choi J., Park H., Kim N., et al. Structure-based development of a receptor activator of nuclear factor-kappaB ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis. Proc Natl Acad Sci U S A 2010, 107:20281-20286.
13. Smolen J.S., Landewe R., Breedveld F.C., Dougados M., Emery P., Gaujoux-Viala C., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975.
14. Inami K., Sawai H., Yakushiji K., Katao Y., Matsumoto N., Domae N. Augmentation of TNF-induced osteoclast differentiation by inhibition of ERK and activation of p38: similar intracellular signaling between RANKL- and TNF-induced osteoclast differentiation. Orthod Waves 2008, 67:150-156.
15. Hashizume M., Hayakawa N., Mihara M. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatology (Oxford) 2008, 47:1635-1640.
16. Romas E., Gillespie M.T., Martin T.J. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 2002, 30:340-346.
17. Stolina M., Schett G., Dwyer D., Vonderfecht S., Middleton S., Duryea D., et al. RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies. Arthritis Res Ther 2009, 11:R187.
18. Schett G., Middleton S., Bolon B., Stolina M., Brown H., Zhu L., et al. Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. Arthritis Rheum 2005, 52:1604-1611.
19. Inoue A., Takahashi K.A., Mazda O., Arai Y., Saito M., Kishida T., et al. Comparison of anti-rheumatic effects of local RNAi-based therapy in collagen induced arthritis rats using various cytokine genes as molecular targets. Mod Rheumatol 2009, 19:125-133.
20. del Guercio M.F., Alexander J., Kubo R.T., Arrhenius T., Maewal A., Appella E., et al. Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo. Vaccine 1997, 15:441-448.
21. Mittenbuhler K., Loleit M., Baier W., Fischer B., Sedelmeier E., Jung G., et al. Drug specific antibodies: T-cell epitope-lipopeptide conjugates are potent adjuvants for small antigens in vivo and in vitro. Int J Immunopharmacol 1997, 19:277-287.
22. Brand D.D., Latham K.A., Rosloniec E.F. Collagen-induced arthritis. Nat Protoc 2007, 2:1269-1275.
23. Brand D.D., Kang A.H., Rosloniec E.F. Immunopathogenesis of collagen arthritis. Springer Semin Immunopathol 2003, 25:3-18.
24. Willard D., Chen W.J., Barrett G., Blackburn K., Bynum J., Consler T., et al. Expression, purification, and characterization of the human receptor activator of NF-kappaB ligand (RANKL) extracellular domain. Protein Expr Purif 2000, 20:48-57.
25. Berglez J., Pilling P., Macreadie I., Fernley R.T. Purification, properties, and crystallization of saccharomyces cerevisiae dihydropterin pyrophosphokinase-dihydropteroate synthase. Protein Expr Purif 2005, 41:355-362.
26. Dalum I., Butler D.M., Jensen M.R., Hindersson P., Steinaa L., Waterston A.M., et al. Therapeutic antibodies elicited by immunization against TNF-alpha. Nat Biotechnol 1999, 17:666-669.
27. Humphreys D.T., Wilson M.R. Modes of L929 cell death induced by TNF-alpha and other cytotoxic agents. Cytokine 1999, 11:773-782.
28. Jin C.H., Chae S.Y., Kim T.H., Yang H.K., Lee E.Y., Song Y.W., et al. Effect of tumor necrosis factor-related apoptosis-inducing ligand on the reduction of joint inflammation in experimental rheumatoid arthritis. J Pharmacol Exp Ther 2010, 332:858-865.
29. Ozdemir O. Flow cytometric mast cell-mediated cytotoxicity assay: a three-color flow cytometric approach using monoclonal antibody staining with annexin V/propidium iodide co-labeling to assess human mast cell-mediated cytotoxicity by fluorosphere-adjusted counts. J Immunol Methods 2011, 365:166-173.
30. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
31. Oliff A., Defeo-Jones D., Boyer M., Martinez D., Kiefer D., Vuocolo G., et al. Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 1987, 50:555-563.
32. Palframan R., Airey M., Moore A., Vugler A., Nesbitt A. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods 2009, 348:36-41.
33. Al-Abd A.M., Inglis J.J., Nofal S.M., Khalifa A.E., Williams R.O., El-Eraky W.I., et al. Nimesulide improves the disease modifying anti-rheumatic profile of methotrexate in mice with collagen-induced arthritis. Eur J Pharmacol 2010, 644:245-250.
34. Cuzzocrea S., Ayroldi E., Di Paola R., Agostini M., Mazzon E., Bruscoli S., et al. Role of glucocorticoid-induced TNF receptor family gene (GITR) in collagen-induced arthritis. FASEB J 2005, 19:1253-1265.
35. Romas E., Sims N.A., Hards D.K., Lindsay M., Quinn J.W., Ryan P.F., et al. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 2002, 161:1419-1427.
36. Nonaka C.F., Cavalcante R.B., Nogueira R.L., de Souza L.B., Pinto L.P. Immunohistochemical analysis of bone resorption regulators (RANKL and OPG), angiogenic index, and myofibroblasts in syndrome and non-syndrome odontogenic keratocysts. Arch Oral Biol 2012, 57:230-237.
37. Semerano L., Assier E., Boissier M.C. Anti-cytokine vaccination: a new biotherapy of autoimmunity?. Autoimmun Rev 2012, 10.1016/j.autrev.2012.02.003.
38. Pesek R., Lockey R. Vaccination of adults with asthma and COPD. Allergy 2011, 66:25-31.
39. Li A.F., Escher A. DNA vaccines for transplantation. Expert Opin Biol Ther 2010, 10:903-915.
40. Bachmann M.F., Dyer M.R. Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nat Rev Drug Discov 2004, 3:81-88.
41. Pettit A.R., Ji H., von Stechow D., Muller R., Goldring S.R., Choi Y., et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001, 159:1689-1699.
42. Roos J.C., Ostor A.J. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006, 355:2046-2047.
43. Cheng T., Pavlos N.J., Wang C., Tan J.W., Lin J.M., Cornish J., et al. Mutations within the TNF-like core domain of RANKL impair osteoclast differentiation and activation. Mol Endocrinol 2009, 23:35-46.
44. Nakao A., Fukushima H., Kajiya H., Ozeki S., Okabe K. RANKL-stimulated TNFalpha production in osteoclast precursor cells promotes osteoclastogenesis by modulating RANK signaling pathways. Biochem Biophys Res Commun 2007, 357:945-950.
45. Zwerina J., Hayer S., Tohidast-Akrad M., Bergmeister H., Redlich K., Feige U., et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 2004, 50:277-290.
46. Saidenberg-Kermanac'h N., Corrado A., Lemeiter D., deVernejoul M.C., Boissier M.C., Cohen-Solal M.E. TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone 2004, 35:1200-1207.
47. Ominsky M.S., Stouch B., Schroeder J., Pyrah I., Stolina M., Smith S.Y., et al. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys. Bone 2011, 49:162-173.